Belimumab for autoimmune hepatitis
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests a drug called belimumab for people with autoimmune hepatitis that is not well controlled. It aims to see if adding belimumab to your current treatment can help reduce liver inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with autoimmune hepatitis for at least 6 months.
- You have active liver inflammation (elevated ALT) or have normal ALT but are on stable immunosuppression.
- You are currently taking corticosteroids or other immunosuppressants (like azathioprine, mycophenolate, or purinethol) for your hepatitis.
- You do not have other liver diseases like hepatitis B or C, or fatty liver disease.
- You do not have advanced liver disease (like severe cirrhosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new biologic medicine called inebilizumab that may help people whose autoimmune hepatitis hasn't improved with standard treatments. The goal is to see if it can reduce liver inflammation and improve their condition.
This study compares two medicines, azathioprine and mycophenolate mofetil, to see which works better for treating autoimmune hepatitis. If you haven't been treated before, this trial could help find a more effective way to manage your condition.
This study looks at what factors affect how well the liver responds to treatment in people with autoimmune hepatitis. It may help doctors understand why some people respond better than others and could lead to more personalized care.
This study looks at fats (lipids) in the blood of people with autoimmune hepatitis to find patterns that might help diagnose or monitor the disease. It may lead to better ways to manage the condition.
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
This study collects information and blood samples from people with autoimmune hepatitis and other liver conditions to better understand these diseases. Taking part may help with research, though it is not a treatment trial.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.